Tag Archives: Phil Nadeau

Rocket Pharmaceuticals Inc Gets a Buy Rating from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. reiterated a Buy rating on Rocket Pharmaceuticals Inc (NASDAQ: RCKT). The company’s shares opened today at $17.61. According to TipRanks.com, Nadeau is a 5-star analyst with an average return

Xoma Corp Receives a Hold from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Xoma Corp (NASDAQ: XOMA). The company’s shares opened today at $22.64. According to TipRanks.com, Nadeau is a 5-star analyst with an average return of

Cowen & Co. Sticks to Their Hold Rating for Zafgen

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Hold rating on Zafgen (NASDAQ: ZFGN). The company’s shares opened today at $6.50. According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.0%

Cowen & Co. Believes GW Pharma (NASDAQ: GWPH) Won’t Stop Here

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on GW Pharma (NASDAQ: GWPH) yesterday and set a price target of $165. The company’s shares opened today at $144.83, close to its 52-week high of $149.95. According to TipRanks.com,

Dynavax Received its Third Buy in a Row

After Cantor Fitzgerald and William Blair assigned a Buy rating to Dynavax in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Phil Nadeau maintained a Buy rating on Dynavax (NASDAQ: DVAX) yesterday and

Cowen & Co. Maintains Their Buy Rating on Spark Therapeutics

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today and set a price target of $85. The company’s shares opened today at $69.77. According to TipRanks.com, Nadeau is a 5-star analyst with an